Outflow-enhancing glaucoma medications may soon be available

Cimberle, Michela
July 2009
Ocular Surgery News;7/10/2009, Vol. 27 Issue 13, p16
Academic Journal
The article reports on the announcement by surgeon Douglass J. Rhee at the "Ocular Surgery News" Symposium held in Rome, Italy from May 22-23, 2009 that glaucoma medications that are available today can be divided into outflow and inflow agents that are directed at enhancing trabecular meshwork flow. He added that research is now focused on outflow agents, including the Rho-kinase (ROCK) inhibitor that is closest to market.


Related Articles

  • Frequently asked questions about latanoprost. Camras, Carl B.; Ritch, Robert // Ophthalmology Times;11/15/97, Vol. 22 Issue 22, p10 

    Part I. Addresses commonly asked questions about latanoprost, one of the most commonly used agents to treat glaucoma. Includes pharmacokinetics of latanoprost; Utilization in infants and children; Lack of systemic side effects.

  • Better compliance possible with combo glaucoma product. Guttman, Cheryl; Schuman, Joel S. // Ophthalmology Times;03/15/2001, Vol. 26 Issue 6, p25 

    Examines the therapeutic use of a combination of ophthalmic drugs for glaucoma patients. Benefits of a combination glaucoma product; Potential for improved safety; Overview of the clinical trials for combination ophthalmic drugs.

  • The Added Effect Of Travatan. Quinn, Christopher J. // Review of Optometry;04/15/2001, Vol. 138 Issue 4, p115 

    Presents several drugs for glaucoma in the United States. Reduction of intraocular pressure through Xalatan; Introduction of Travatan by Alcon; Dosage and side effect of Travatan; Prevalence of glaucoma in African-American races.

  • Frequently asked questions about latanoprost. Camras, Carl B. // Ophthalmology Times;12/01/97, Vol. 22 Issue 23, p7 

    Part II. Provides answers to questions on the glaucoma medication, latanoprost. Effectivity of latanoprost in several types of glaucoma; Latanoprost with nonsteroidal anti-inflammatory drugs; Stability of latanoprost; When to use the medication in glaucoma therapy.

  • Systemic Effects of Medications Used to Treat Glaucoma. Everitt, Daniel E. // Annals of Internal Medicine;1/15/90, Vol. 112 Issue 2, p120 

    Discusses the systemic effects of medications used to treat glaucoma. Nature of glaucoma; Effects of ophthalmic drugs when treating patients with glaucoma; Agents commonly used to treat glaucoma.

  • Hypotensive Eye Drops Can Prevent Or Delay Glaucoma In High-Risk Patients.  // RN;Aug2002, Vol. 65 Issue 8, p16 

    Reports the effect of hypotensive eye drops on primary open-angle glaucoma. Reduction of the intraocular pressure; Considerations in the administration of ocular hypotensive medication; Role of elevated intracranial pressure in the development of glaucoma.

  • A New Option for Glaucoma Patients. Netland, Peter // Review of Ophthalmology;Oct2000, Vol. 7 Issue 10, p63 

    Introduces Rescula, an opthalmic solution for glaucoma treatment by CIBA Vision. Pharmacologic properties and mechanism of action of the drug; Details on the efficacy and safety of using the drug alone; Effectiveness of the drug as an adjunctive therapy; Prescribing information.

  • Travoprost.  // Reactions Weekly;4/6/2013, Issue 1447, p33 

    The article presents a case study of a 78-year-old woman who developed hypertrichosis in eyelashes of one eye following treatment of travoprost for glaucoma.

  • New therapeutic class enters the fight against glaucoma. Portyansky Beyzarov, Elena // Drug Topics;9/18/2000, Vol. 144 Issue 18, p27 

    Reports on the approval of Rescula, an ophthalmic solution manufactured by Ciba Vision for treatment of glaucoma. Comparison with other glaucoma drugs; Side effects of unoprostone; Efficacy of the solution.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics